The authors verified the superiority of M-CTX-Fc by comparing U251MG-P1 cells (CD44+) with CD44-negative cells (SKBR3) in cellular uptake, in vitro cytotoxicities and in vivo tumor growth inhibition. The gene discussed is CD44; the disease is neoplasm.